LONDON, July 24 (Reuters) - European regulators on Friday recommended the use of a combination of Novartis's drugs Tafinlar and Mekinist for treating certain patients with melanoma, boosting prospects for medicines acquired from GlaxoSmithKline. The Swiss drugmaker said the U.S. Food and D
Read more* EU regulators back GSK's Mosquirix for babies in Africa * Product is first human vaccine against a parasitic disease * Mosquito-borne malaria infects 200 million people a year * WHO to assess vaccine in October before possible rollout (Adds WHO giving date for its review, WH
Read more(ShareCast News) - Investors braved weaker than expected readings on Chinese and Eurozone manufacturing and lingering worries regarding Greece, allowing the top flight index to recover after dipping at the start of trading. As of 09:05 the Footsie was 7.34 points higher to end at 6,665.30. Stocks r
Read more(ShareCast News) - Healthcare giant GlaxoSmithKline said its malaria vaccine has passed its last scientific hurdle, although the immunisation programme in sub-Saharan Africa could be still over 12 months away. On Thursday, the treatment, aimed at young children, was given a positive scientific opini
Read more(Corrects to remove reference to need for European Commission approval) * Vaccine developed by GlaxoSmithKline for babies in Africa * WHO will now decide whether to recommend vaccine for use * GSK scientist worked on the vaccine for almost 30 years By Kate Kelland, Health
Read more* GSK's Mosquirix will be approved for babies in Africa * Vaccine is first human vaccine against parasitic disease * Mosquito-borne Malaria infects around 200 people a year * The disease killed 584,000 in 2013, most of them children (Adds quotes, bullets, details on pricing, i
Read more** GlaxoSmithKline slips 1.4% as Morgan Stanley warns margins likely to decline 260 bp when drugmaker reports Q2 results on July 29 ** Margins pressure reflects continuous decline in sales of lung drug Advair and revamp of portfolio after big Novartis asset swap ** Broker says GSK's
Read more